591 related articles for article (PubMed ID: 30576610)
21. Emerging drugs for the treatment of axial spondyloarthritis.
Rademacher J; Poddubnyy D
Expert Opin Emerg Drugs; 2018 Mar; 23(1):83-96. PubMed ID: 29475394
[TBL] [Abstract][Full Text] [Related]
22. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
23. Ixekizumab for the treatment of ankylosing spondylitis.
Huang JX; Lee YH; Wei JC
Expert Rev Clin Immunol; 2020 Aug; 16(8):745-750. PubMed ID: 32729361
[TBL] [Abstract][Full Text] [Related]
24. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
25. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA; Dhillon S
Drugs; 2016 Jul; 76(10):1023-30. PubMed ID: 27255593
[TBL] [Abstract][Full Text] [Related]
27. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
29. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
31. Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.
Purmonen T; Törmälehto S; Wahlman H; Puolakka K
J Med Econ; 2019 Feb; 22(2):151-157. PubMed ID: 30474450
[TBL] [Abstract][Full Text] [Related]
32. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
Blauvelt A
Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Baraliakos X; Kivitz AJ; Deodhar AA; Braun J; Wei JC; Delicha EM; Talloczy Z; Porter B;
Clin Exp Rheumatol; 2018; 36(1):50-55. PubMed ID: 28516874
[TBL] [Abstract][Full Text] [Related]
34. Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
[TBL] [Abstract][Full Text] [Related]
35. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
36. Anti-IL-17 phase II data for psoriasis: A review.
Brown G; Malakouti M; Wang E; Koo JY; Levin E
J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447
[TBL] [Abstract][Full Text] [Related]
37. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
McGonagle DG; McInnes IB; Kirkham BW; Sherlock J; Moots R
Ann Rheum Dis; 2019 Sep; 78(9):1167-1178. PubMed ID: 31278139
[TBL] [Abstract][Full Text] [Related]
38. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
39. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
40. IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
Baeten D; Adamopoulos IE
Front Immunol; 2020; 11():623874. PubMed ID: 33679714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
